Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLM+VIT vaccine
- Development stage
- Preclinical
- Lead developer
- Virothera Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
VLM+VIT vaccine is a DNA-based immunotherapy being developed by Virothera Pharmaceuticals for the treatment of Herpes Simplex Virus type 2 (HSV-2). The vaccine utilizes a dual-component system consisting of Virus-Like Membranes (VLM) and Virokine Immune Therapeutic (VIT) technology. This approach is designed to target chemokine receptors on T regulatory (Treg) cells, aiming to modulate the local immune environment and counteract the immunosuppressive mechanisms employed by the virus. Currently in the IND-enabling phase, the therapy represents a nucleic acid-based strategy to provide therapeutic or prophylactic benefit against chronic HSV-2 infection.
- Other names
- HSV-2 VLM + VIT vaccine
02
Targets
HSV-2 (Herpes simplex virus 2)
Beyond the preview
Go deeper on VLM+VIT vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLM+VIT vaccine.